Insider trade

Officer sold ~$1.21M of MRK shares in the open market

Traded Feb 12, 2026 · Filed Feb 12, 2026

MerckMRK

~$1.21M
Reported value · 10K sh @ $121.4562: 61K
Holds after · shares reported: +20.6%
stock since the trade · S&P 500 +12.1%, $119.24 → $143.81 on Oct 1

Why it stands out

Merck's Chief Marketing Officer sold $1.21M of Merck shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 12, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 12, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,214,562

Shares × reported transaction price

Timing vs results

9 days after results of Feb 3, 2026, 77 days before results of Apr 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $119.24 on Feb 12, 2026, within 3% of its 52-week high, after a 12% rise over the previous 30 trading days

52-week range $73.47 (May 14, 2025) to $121.93 (Feb 6, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $106.06 on Dec 30, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.

IN RE MERCK & CO., INC. SECURITIES LITIGATION, docket 2:25-cv-01208, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Keytruda on Feb 10, 2026, 2 days before this trade.

New use approved (efficacy supplement). Active ingredient: Pembrolizumab. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.7%	+1.1%	-0.4%
30 days	-4.9%	-1.9%	-3.1%
90 days	-6.6%	+9.7%	-16.3%
180 days	+9.5%	+13.3%	-3.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0000310158-26-000052
Filed / recorded: Feb 12, 2026, 9:02 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Merck & Co., Inc.
Issuer CIK: 310158
Ticker: MRK
Reporting person: Chirfi Guindo
Relationship: Officer
Officer title: Chief Marketing Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 12, 2026
Transaction code: S
Shares / units: 10,000
Price per share: $121.4562
Acquired / disposed: Disposed (D)
Shares owned after: 60,615.127
Ownership form: Direct
Amendment: No

Footnotes from the filing

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.4400 to $121.5150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Around the same time

Officer sold8mo ago

~$1.2MReported value · 10K sh @ $117.5226

Merck's Executive VP & President, MRL sold $1.2M of Merck shares. Nobody planned it ahead of time.

Why it stands out Official record

Officer sold8mo ago

~$1.18MReported value · 10K sh @ $118.4101

Merck's Chief Marketing Officer sold $1.18M of Merck shares. Nobody planned it ahead of time.

Why it stands out Official record

8mo ago

26KShares · @ $119.1522

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record